155 results
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
29 May 14
Regulation FD Disclosure
12:00am
of Patients --
-- Phase 3 Study Planned for 2014, With Special Protocol Assessment --
NEW YORK, May 29, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS … is initiating a Phase 3 study of Melapuldencel-T later this year under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration
8-K
EX-10.1
LSTA
Lisata Therapeutics Inc
19 Nov 07
Entry into a Material Definitive Agreement
12:00am
is adversely decided against it. SCTI has not
received any notice of assessment or proposed assessment in connection with any
tax returns, nor is SCTI … a party to or to the best of its knowledge, expected to
become a party to any pending or threatened action or proceeding, assessment or
collection
8-K
EX-99.1
LSTA
Lisata Therapeutics Inc
14 Apr 14
Entry into a Material Definitive Agreement
12:00am
clinical trial with Special Protocol Assessment (SPA) and received Fast Track designation for metastatic melanoma, as well as Orphan Drug designation … has received Special Protocol Assessment (SPA), indicating that the Food and Drug Administration (FDA) is in agreement with the design, clinical
8-K
EX-99.1
ppa4lxmws
20 Mar 13
Other Events
12:00am
8-K
EX-99.1
ei74qam99gao2m2
30 Jul 08
Unregistered Sales of Equity Securities
12:00am
8-K
EX-99.1
ecr3ow9m r41c3rt
29 Sep 14
NeoStem Secures Debt Facility
12:00am
8-K
EX-99.2
21k51y7eaqjy
14 Aug 23
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.2
sfev cf8p
2 Nov 23
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
4:10pm
8-K
EX-99.2
zhn w5hof58
30 Mar 23
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:07pm
8-K
EX-99.2
at5pb
29 Feb 24
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
4:09pm
8-K
EX-99.2
i04lf3g6 l3291
9 May 23
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.2
2348e4ht1 mso7x
9 May 24
Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:08pm
8-K
EX-99.1
8g10tl3
18 Apr 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
cgeundvnozio6
10 May 18
Caladrius Biosciences Reports 2018 First Quarter Financial Results
4:07pm